683 Capital Management, LLC Adma Biologics, Inc. Transaction History

683 Capital Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.43 - $2.2 $318,322 - $489,726	-222,603 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$1.28 - $1.83 $103,946 - $148,610	-81,208 Reduced 26.73%	222,603 $407,000
Q4 2021 Feb 14, 2022	BUY	$1.09 - $1.66 $331,153 - $504,326	303,811 New	303,811 $428,000
Q1 2021 May 17, 2021	SELL	$1.67 - $2.95 $3.34 Million - $5.9 Million	-2,000,000 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$1.5 - $4.59 $1.95 Million - $5.97 Million	1,300,000 Added 185.71%	2,000,000 $5.76 Million
Q4 2019 Feb 14, 2020	SELL	$3.89 - $5.15 $2.82 Million - $3.73 Million	-724,378 Reduced 50.86%	700,000 $2.8 Million
Q2 2019 Aug 14, 2019	BUY	$3.52 - $5.24 $2.18 Million - $3.25 Million	619,378 Added 76.94%	1,424,378 $5.51 Million
Q3 2018 Nov 14, 2018	SELL	$4.39 - $6.85 $351,200 - $548,000	-80,000 Reduced 9.04%	805,000 $5 Million
Q2 2018 Aug 14, 2018	BUY	$4.39 - $5.44 $351,200 - $435,200	80,000 Added 9.94%	885,000 $3.99 Million
Q1 2018 May 15, 2018	SELL	$3.21 - $5.21 $465,450 - $755,450	-145,000 Reduced 15.26%	805,000 $3.7 Million
Q4 2017 Feb 14, 2018	BUY	$2.06 - $3.24 $1.96 Million - $3.08 Million	950,000	950,000 $3.05 Million

319

185M

917K

91.6K

Ticker ADMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 196,356,992
Market Cap $3.91B
Description
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...

Get notified when there are updates to the investment portfolio of 683 Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on 683 Capital Management, LLC with notifications on news.